DNA base editing could enable better probiotic strains

Researchers at Kobe University have managed to edit the DNA of Lactobacillus strains directly without a template from other organisms. Their gene editing technique has enabled the researchers to create a strain that doesn’t produce diabetes-aggravating chemicals.

Humans have improved the microorganisms we rely on for millennia, selecting variants that are better able to produce wine, yoghurt, natto and many other products. More recently, direct genetic modification has emerged as a tool to exert more precise and efficient control over the improvement, but also has drawn much public criticism for often using DNA from unrelated organisms in these modifications.

“As a consequence, using such transgenic techniques is not favourable for food products due to legislations being restrictive and social acceptance being low,” noted Kobe University bioengineer Keiji Nishida. With this in mind, Nishida and his team developed a technique that gives even more precise control over the genetic content of a microorganism that does not rely on template DNA from other organisms.

Nishida and his team have now teamed up with Kobe University venture Bio Palette Co., Ltd. and successfully applied their technique to industrially important Lactobacillus strains used in manufacturing dairy products and pickles, as reported in the journal Applied Microbiology and Biotechnology.

“We edited individual, targeted locations in the genome at almost 100% efficiency in two major but fairly different Lactobacillus species,” Nishida explained. “This shows that the technique can be readily applied to a wide range of strains.”

To further showcase the capabilities of their approach, they focused on a gene that is involved in the production of a chemical that aggravates type 2 diabetes. By using Target-AID to mutate that gene, they engineered a Lactobacillus strain that could produce yoghurt with less than a tenth of that chemical, making it safer to consume for people with type 2 diabetes.

“The bacteria we produced are not subject to regulations concerning genetically modified organisms when used as foods, supplements or medicines; we thus expect that they can be readily commercialised after appropriate safety confirmation,” Nishida said.

Image ©Keiji Nishida (CC BY-ND-NC)